Zuckerberg California Wealth Tax Deal Explained
Mark Zuckerberg’s reported agreement with Meta has energized wealth tax advocates, but its terms, legal status, and broader economic implications remain uncertain.
How Apps Could Unlock the iPhone Duo’s Potential
The iPhone Duo remains unconfirmed, but research, creativity, finance, photography, and AI apps show how dual-screen software could make the concept useful.
Why the U.S. Still Lags on Driverless Trains
The technology for driverless trains already exists. U.S. transit agencies lag because aging infrastructure, fragmented governance, labor concerns, funding limits, and public skepticism slow adoption.
Apple Pro and Tell Event: What to Expect
Apple’s reported October 28 event may focus on MacBook updates, professional hardware, and Apple silicon. An OLED iPad mini and touchscreen MacBook Pro remain unconfirmed.
Engadget Review Recap: iPhones, Rivian R2, and More
Engadget’s October 24, 2026 roundup covers two iPhones, Rivian’s R2, and other products, but the available source omits key review details.
iPhone Duo Apple Store Pickup Returns in U.S. and Canada
Apple Store pickup for the iPhone Duo has reportedly returned in the U.S. and Canada. Check local inventory, confirm your order, and wait for pickup approval.
He Thought It Was Gout. A Clinical Trial Saved His Life
A patient who thought he had gout was later considered for hospice care. An experimental clinical-trial treatment reportedly changed his prognosis, although key medical details remain unknown.
178 Additional Measles Cases Reported in US Outbreak
US health authorities reportedly identified 178 additional measles cases. The figure requires verification against the latest CDC data and reporting period.
Barnes Ice Cap Growth Reversed by Human Warming
The Barnes Ice Cap may have expanded for 2,000 years before human-caused warming halted or reversed its growth, offering context for modern Arctic ice loss.
Genomic Test May Refine Abiraterone Treatment
A reported genomic test may help identify prostate cancer patients more likely to benefit from abiraterone, but clinical validation and regulatory details remain unclear.